gauthier_therapy

01 p 0001 versus placebo statistical placebo n 181

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: 0 Donepezil 10 mg/day Donepezil 5 mg/day Placebo 1 6 1 2 Study week 8 n = 194 188 194 Donepezil 5 mg n = 201 193 199 ** p < 0.01; *** p < 0.001 versus placebo. Statistical Placebo n = 181 180 analyses were conducted on the observed cases at 180 Weeks 6, 12, 18, and 24, and at endpoint (Week 24 LOCF) by ANCOVA. Clinical decline 2 4 ITT LOCF 172 163 155 183 173 164 167 160 150 © TND 2005 LS mean change from baseline M M S E s c or e Donepezil in VaD: LS Mean Change Donepezil in MMSE in 2 *** 0 – 10 Donepezil 10 mg *** 1 ** * *** ** *** *** Clinical improvement Baseline Donepezil 10 mg/day Donepezil 5 mg/day Placebo 6 12 Clinical decline 1 8 Study week n = 203 197 179 203 Donepezil 5 mg n = 203 196 185 202 * Placebo ** p ≤ 0.01; *** p < 0.001 versus placebo. 174 p < 0.05; n = 188 188 Statistical analyses were conducted on the observed cases 188 at Weeks 6, 12, 18, and 24, and at endpoint (Week 24 LOCF) by ANCOVA. 2 4 ITT LOCF 169 161 175 166 156 157 © TND 2005 Erkinjuntti Trial: Change in Change ADAS-cog Placebo/Reminyl in ADAS-cog from baseline Mean (± SE) change –3 Reminyl/Reminyl * * –2 Improvemen t * * –1 0 1 2 Double-blind phase BaselineWeek 6 Month 3 PLA/GAL (n) (116) GAL/GAL (n) (239) Open-...
View Full Document

This document was uploaded on 03/07/2014 for the course BIOLOGY BIO at NYU.

Ask a homework question - tutors are online